Activity Overview
This educational activity is an archive of the live presentation held on May 30, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This
educational activity is directed toward oncologists, NPs/PAs, nurses,
pharmacists, and other HCPs involved in the management of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Differentiate the impact of HER2 mutations, amplifications, and HER2 protein overexpression on managing advanced NSCLC
- Construct treatment plans for patients with advanced NSCLC harboring HER2 alterations based on the most up to date clinical trial safety and efficacy data
- Evaluate patient eligibility for TROP2-targeted ADCs in advanced NSCLC with and without targetable genomic alterations
- Formulate plans to mitigate adverse events associated with HER2- and TROP2-directed therapies in NSCLC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
